Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
With a 77% revenue increase and a growing subscriber base, Hims & Hers Health Inc (HIMS) continues to innovate in ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS – Research Report) today. The company’s shares closed yesterday at $20.76. According to TipRanks, ...
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Seaport Global analyst Aaron Kessler maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price ...
Ladies and gentlemen, thank you for standing by. My name is Krista and I will be your conference operator today. At this time, I would like to welcome everyone to His & Hers third-quarter earnings ...
Stocktwits on MSN21h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 PerformanceHims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback